PAR-5359, a well-balanced PPARα/γ dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo

European Journal of Pharmacology

Volumn 595, Issue 1-3, 2008, Pages 119-125

  Kim, Mi Kyung ^a   Chae, Yu Na ^a   Son, Moon Ho ^a   Kim, Soon Hoe ^a   Kim, Jin Kwan ^a   Moon, Ho Sang ^a   Park, Chan Sun ^b   Bae, Myung Ho ^b   Kim, Eunkyung ^b   Han, Taedong ^b   Choi, Hyun ho ^b   Shin, Young Ah ^b   Ahn, Byung Nak ^b   Lee, Chun Ho ^b   Lim, Joong In ^a   Shin, Chang Yell ^a  

^a Dong A Pharmaceutical Company   (South Korea)

^b Yuhan Research Institute   (South Korea)

Author keywords

Dyslipidemia; Gemfibrozil; Insulin resistance; PAR 5359; PPARalpha gamma dual agonist; Rosiglitazone

Indexed keywords

3 [4 [2 [4 (4 CHLOROPHENYL) 3,6 DIHYDRO 2H PYRIDIN 1 YL]ETHOXY]PHENYL]ETHOXYPROPIONIC ACID; APOLIPOPROTEIN A1; DRUG VEHICLE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PAR 5359; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RECEPTOR SUBTYPE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CHOLESTEROL INTAKE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; HYPOLIPEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSACTIVATION;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; BLOOD GLUCOSE; CELL LINE, TUMOR; CELLS, CULTURED; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, OBESE; OBESITY; PPAR ALPHA; PPAR GAMMA; PROPIONIC ACIDS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 52049096652     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.066     Document Type: Article

References (37)

1. Balakumar P., Rose M., Ganti S.S., Krishan P., and Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol. Res. 56 (2007) 91-98
2. Behre C.J. Adiponectin, obesity and atherosclerosis. Scand. J. Clin. Lab. Invest. 67 (2007) 449-458
3. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
4. Brun R.P., Tontonoz P., Forman B.M., Ellis R., Chen J., Evans R.M., and Spiegelman B.M. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10 (1996) 974-984
5. Cha D.R., Zhang X., Zhang Y., Wu J., Su D., Han J.Y., Fang X., Yu B., Breyer M.D., and Guan Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56 (2007) 2036-2045
6. Chaput E., Saladin R., Silvestre M., and Edgar A.D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 271 (2000) 445-450
7. Chira E.C., McMillen T.S., Wang S., Haw III A., O'Brien K.D., Wight T.N., and Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195 (2007) 100-109
8. Davis T. Tesaglitazar AstraZeneca. IDrugs 5 (2002) 924-926
9. Doebber T.W., Kelly L.J., Zhou G., Meurer R., Biswas C., Li Y., Wu M.S., Ippolito M.C., Chao Y.S., Wang P.R., Wright S.D., Moller D.E., and Berger J.P. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochem. Biophys. Res. Commun. 318 (2004) 323-328
10. Duval C., Muller M., and Kersten S. PPARalpha and dyslipidemia. Biochim. Biophys. Acta 1771 (2007) 961-971
11. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., Pugh K., Jenkins A.J., Klein R.L., and Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
12. Harrity T., Farrelly D., Tieman A., Chu C., Kunselman L., Gu L., Ponticiello R., Cap M., Qu F., Shao C., Wang W., Zhang H., Fenderson W., Chen S., Devasthale P., Jeon Y., Seethala R., Yang W.P., Ren J., Zhou M., Ryono D., Biller S., Mookhtiar K.A., Wetterau J., Gregg R., Cheng P.T., and Hariharan N. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 55 (2006) 240-248
13. Huttunen J.K., Manninen V., Manttari M., Koskinen P., Romo M., Tenkanen L., Heinonen O.P., and Frick M.H. The Helsinki Heart Study: central findings and clinical implications. Ann. Med. 23 (1991) 155-159
14. Jaspan J.B. Monitoring and controlling the patient with non-insulin-dependent diabetes mellitus. Metabolism 36 (1987) 22-27
15. Jia X., Chen Y., Zidichouski J., Zhang J., Sun C., and Wang Y. Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats. Atherosclerosis (2008) 10.1016/j. atherosclerosis. 2008.03.008
16. Kanatani Y., Usui I., Ishizuka K., Bukhari A., Fujisaka S., Urakaze M., Haruta T., Kishimoto T., Naka T., and Kobayashi M. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56 (2007) 795-803
17. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 (2005) 1419-1424
18. Krause B.R., and Princen H.M. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?. Atherosclerosis 140 (1998) 15-24
19. Krzyzanowska K., Mittermayer F., Krugluger W., Roden M., Schernthaner G., and Wolzt M. Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone. Horm. Metab. Res. 39 (2007) 769-772
20. Ljung B., Bamberg K., Dahllof B., Kjellstedt A., Oakes N.D., Ostling J., Svensson L., and Camejo G. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. 43 (2002) 1855-1863
21. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414 (2001) 821-827
22. Nakano S., Inada Y., Masuzaki H., Tanaka T., Yasue S., Ishii T., Arai N., Ebihara K., Hosoda K., Maruyama K., Yamazaki Y., Shibata N., and Nakao K. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E1213-1222
23. Pickavance L.C., Brand C.L., Wassermann K., and Wilding J.P. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br. J. Pharmacol. 144 (2005) 308-316
24. Pickavance L.C., Tadayyon M., Widdowson P.S., Buckingham R.E., and Wilding J.P. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br. J. Pharmacol. 128 (1999) 1570-1576
25. Porte Jr. D., and Schwartz M.W. Diabetes complications: why is glucose potentially toxic?. Science 272 (1996) 699-700
26. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90 (2002) 89-94
27. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., Faas F.H., and Anderson J.W. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162 (2002) 2597-2604
28. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., and Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278 (2000) 704-711
29. Sauerberg P., Pettersson I., Jeppesen L., Bury P.S., Mogensen J.P., Wassermann K., Brand C.L., Sturis J., Woldike H.F., Fleckner J., Andersen A.S., Mortensen S.B., Svensson L.A., Rasmussen H.B., Lehmann S.V., Polivka Z., Sindelar K., Panajotova V., Ynddal L., and Wulff E.M. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45 (2002) 789-804
30. Schuster H., Fagerberg B., Edwards S., Halmos T., Lopatynski J., Stender S., Birketvedt G.S., Tonstad S., Gause-Nilsson I., Halldorsdottir S., and Ohman K.P. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 197 (2008) 355-362
31. Sharabi Y., Oron-Herman M., Kamari Y., Avni I., Peleg E., Shabtay Z., Grossman E., and Shamiss A. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am. J. Hypertens. 20 (2007) 206-210
32. Sharma S., Sowjanya A., Kumari M., Suryaprakash R., Cynthia G., Suresh J., and Chakrabarti R. Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar. Life Sci. 80 (2006) 235-244
33. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
34. van Wijk J.P., de Koning E.J., Martens E.P., and Rabelink T.J. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1744-1749
35. Watts G.F., and Dimmitt S.B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr. Opin. Lipidol. 10 (1999) 561-574
36. Yamaguchi, M., Shibata, Y., Ohta, M., Kagechika, K., Usui, H., Ohta, T., 2007. Novel zwitterionic phenoxyacetic acid derivatives as potent PPAR agonist, 234th ACS Natl Meet, Abst MEDI 161.
37. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., Sorensen R.V., Larsen P.J., Cooney G.J., Wassermann K., and Kraegen E.W. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E531-540